Table 2.
SURs and SIRs for CLABSIs and CAUTIs Before and During the COVID-19 Pandemic
| Variable | Pre–COVID-19 (Mar 2019–Feb 2020) | COVID-19 (Mar–Aug 2020) | Pre–COVID-19 vs COVID-19 | ||||
|---|---|---|---|---|---|---|---|
| SUR | Utilization | Predicted Utilization | Ratio | Utilization | Predicted Utilization | Ratio | Relative Change, % (P Value) |
| Central-line SUR | 537,124 | 609,722 | 0.88 | 257,898 | 279,143 | 0.92 | 4.9 (<.001) |
| Urinary catheter SUR | 546,952 | 695,362 | 0.79 | 270,315 | 319,929 | 0.84 | 7.4% (<.001) |
| SIR | Reported Infections | Predicted Infections | Ratio | Reported Infections | Predicted Infections | Ratio | Relative Change, % (P Value) |
| CLABSI dSIRa | 302 | 520 | 0.58 | 219 | 252 | 0.87 | 49.6 (<.001) |
| CLABSI pSIRb | 302 | 593 | 0.51 | 219 | 272 | 0.81 | 58.4 (<.001) |
| CAUTI dSIRa | 471 | 660 | 0.71 | 209 | 325 | 0.64 | −9.8 (.21) |
| CAUTI pSIRb | 471 | 807 | 0.58 | 209 | 368 | 0.57 | −2.8 (.73) |
Note. SUR, standardized utilization ratio; SIR, standardized infection ratio; CLABSI, central-line–associated bloodstream infection; CAUTI, catheter-associated urinary tract infection;
a
Device standardized infection ratio.
b
Population standardized infection ratio.